U.S. License Holder:
AstraZeneca AB
Date of License:
October-21-2022
Last Update:
Oct-23-2024
FDA-Approved Indications
IMJUDO (tremelimumab-actl) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated:
In combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC);
In combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.